利伐沙班在肥胖患者减重手术前后的单剂量药动学与药效学研究
本研究为单中心1期临床试验,纳入6例Roux-en-Y胃旁路术和6例袖状胃切除术肥胖患者,术前1天和术后3天各单次口服利伐沙班10 mg,评估24小时PK/PD参数。结果显示减重手术未对利伐沙班PK产生临床相关改变,PD指标支持术后有效预防性抗凝,药物耐受良好。
要点
- 减重手术未对利伐沙班PK产生临床相关改变。
- PD指标变化支持术后有效预防性抗凝。
- 利伐沙班耐受良好,未观察到相关安全性问题。
核心结论
- 减重手术似乎未以临床相关方式改变利伐沙班的药动学。
- 药效学变化支持减重术后有效的预防性抗凝。
- 利伐沙班耐受良好,未观察到相关安全性问题。
研究设计与样本
- 单中心1期临床试验,肥胖患者术前1天和术后3天各单次口服利伐沙班10 mg,评估基线及给药后24小时PK/PD参数。
- 6例Roux-en-Y胃旁路术患者和6例袖状胃切除术患者完成研究。
主要发现
- 袖状胃切除术患者术前利伐沙班AUC为971.9 μg·h l-1(CV 10.6%),Cmax为135.3 μg l-1(26.7%),Tmax为1.5 h,终末半衰期为13.1 h(34.1%);术后分别为1165.8(21.9%)、170.0(15.9%)、1.5 h和8.9 h(44.6%)。
- Roux-en-Y胃旁路术患者术前AUC为933.7 μg·h l-1(22.3%),Cmax为136.5 μg l-1(10.7%),Tmax为1.5 h,终末半衰期为13.8 h(46.6%);术后分别为1029.4(7.4%)、110.8(31.8%)、2.5 h和15 h(60.0%)。
- 凝血酶原片段F1+2在术前和术后前12小时内下降,此后升高。
- 凝血酶-抗凝血酶复合物在术前1-3小时内下降,术后保持低水平直至给药后24小时升高。
关键数值与推荐
- 利伐沙班单次口服剂量为10 mg。
- PK/PD评估时间点为基线及给药后24小时内。
临床怎么用
- 减重手术前后使用利伐沙班10 mg单次给药时无需因手术本身调整剂量,但需结合患者个体情况评估。
- 术后可通过药效学指标变化监测抗凝效果。
局限性
- 研究样本量小,仅纳入12例完成研究的患者。
- 单次给药设计,未评估多次给药或长期抗凝效果。
- 仅涉及两种减重手术方式,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Venous thromboembolism is an important cause of postoperative morbidity and mortality in bariatric surgery. Studies of direct oral anticoagulants (DOACs) are not available in this surgical field. The objective of this phase 1 clinical trial was to investigate pharmacokinetic and pharmacodynamic (PK/PD) parameters of rivaroxaban in bariatric patients. METHODS: In this single-centre study, obese patients received single oral doses of rivaroxaban (10 mg) 1 day prior to and 3 days after bariatric surgery. PK and PD parameters were assessed at baseline and during 24 h after drug ingestion. RESULTS: Six Roux-en-Y gastric bypass patients and six sleeve gastrectomy patients completed the study. Mean rivaroxaban area under plasma concentration-time curve, peak plasma concentration, time to peak plasma concentration and terminal half-life were 971.9 μg·h l-1 (coefficient of variation: 10.6), 135.3 μg l-1 (26.7), 1.5 h and 13.1 h (34.1) prior to and 1165.8 (21.9), 170.0 (15.9), 1.5 and 8.9 (44.6) postsurgery for SG patients and 933.7 μg·h l-1 (22.3), 136.5 μg l-1 (10.7), 1.5 h und 13.8 h (46.6) prior to and 1029.4 (7.4), 110.8 (31.8), 2.5 and 15 (60.0) postsurgery for Roux-en-Y gastric bypass patients, respectively. Prothrombin fragments (F1 + 2) decreased during the first 12 hours and increased thereafter in the pre- and the postbariatric setting. Thrombin-antithrombin complexes dropped within 1-3 h in the prebariatric setting and remained low after surgery until they increased at 24 h postdose. Rivaroxaban was well tolerated and no relevant safety issues were observed. CONCLUSIONS: Bariatric surgery does not appear to alter PK of rivaroxaban in a clinically relevant way. Effective prophylactic postbariatric anticoagulation is supported by changes in PD.
引用
- Kröll D, Stirnimann G, Vogt A, et al. Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. Br J Clin Pharmacol. 2017. PMID: 28121368. doi:10.1111/bcp.13243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。